Researchers found that Saxenda by Novo Nordisk reduced both AHI and body weight in patients with moderate or severe sleep apnea who were unable or unwilling to use CPAP, reports Helio.

“Greater im­provements in sleep apnea endpoints and quality of life were significantly asso­ciated with greater weight loss, irrespective of how the weight loss was achieved,” the researchers wrote. “The safety profile for liraglutide 3 mg was generally consistent with that seen with liraglutide in type 2 diabetes.”